BIOPOR Bioporto A/S

Changes in number of shares and votes

Changes in number of shares and votes

June 28, 2019

Announcement no. 10

Changes in number of shares and votes

Completion of share capital increase

The Board of Directors of BioPorto A/S (“BioPorto”) decided on June 17, 2019 to partially exercise the authorization in article 16b of the company’s Articles of Association to issue 9,256,577 new shares in a private placement to a limited number of domestic and international shareholders, institutional and financial investors (company announcement no. 8 of June 17, 2019).

Completion of the issue

BioPorto has now received the full subscription amount and the capital increase of in total nominally DKK 9,256,577 has been registered and completed with the Danish Business Authority.

BioPorto’s gross proceeds from the issue will amount to DKK 36,748,610 equivalent to USD 5.5 million. The aggregate net proceeds are expected to amount to DKK 36,013,610 after deduction of costs. The new shares are equivalent to 5.59% of BioPorto’s registered share capital prior to the share capital increase and is exempt from the requirement to publish a prospectus.

Admission to trading and official listing

The new shares have the same rights as the existing shares. The new shares are entitled to dividend from the time when the share capital increase is registered with the Danish Business Authority. The new shares will as soon as possible be admitted to trading and official listing on Nasdaq Copenhagen A/S under the ISIN code of the company’s existing shares (ISIN DK0011048619).

Share Capital and Votes

Pursuant to section 32 of the Danish Capital Markets Act, BioPorto’s nominal share capital amounts to DKK 174,944,375 consisting of 174,944,375 shares of DKK 1.00 equivalent to 174,944,375 votes. BioPorto’s Articles of Association have been updated accordingly and are available on the company’s website.

For further information, please contact:

Peter Mørch Eriksen, CEO

Ole Larsen, CFO

Telephone , e-mail:

About BioPorto

BioPorto is an in-vitro diagnostics company that provides healthcare professionals in clinical and research settings a range of diagnostic tests and antibodies. BioPorto has its headquarters in Hellerup, Denmark and is listed on the NASDAQ Copenhagen stock exchange.

 

Attachment

EN
28/06/2019

Underlying

BIOPORBioporto A/S

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Bioporto A/S

 PRESS RELEASE
Free
BIOPOR BIOPORTO A/S

BioPorto A/S udnævner CFO

BioPorto A/S udnævner CFO 9. februar, 2026Meddelelse nr. 2 BioPorto A/S udnævner CFO BioPorto A/S (BioPorto) (CPH:BIOPOR) annoncerede i dag udnævnelsen af Klaus Juhl Wulff som ny Executive Vice President (EVP) og Chief Financial Officer (CFO) samt medlem af Executive Management-teamet senest pr. 1. maj 2026. Klaus Juhl Wulff er en højt kvalificeret leder med mere end 20 års erfaring inden for finans, drift, M&A og kapitalmarkeder. Han kommer til BioPorto fra AquaPorin A/S, hvor han var CFO fra 2022. Før dette har Klaus Juhl Wulff fungeret som CFO i forskellige virksomheder. Klaus Juhl W...

February 9, 2026 1 EN
 PRESS RELEASE
Free
BIOPOR BIOPORTO A/S

BioPorto A/S Appoints Chief Financial Officer

BioPorto A/S Appoints Chief Financial Officer February 9, 2026Announcement no. 2 BioPorto A/S Appoints Chief Financial Officer BioPorto A/S (BioPorto) (CPH:BIOPOR) today announced the appointment of Klaus Juhl Wulff as its new Executive Vice President (EVP) and Chief Financial Officer (CFO), and member of the Executive Management team as of latest May 1st, 2026. Klaus Juhl Wulff is a highly skilled leader with more than 20 years of experience in finance, operations, M&A and capital markets. He joins BioPorto from AquaPorin A/S, where he served as CFO from 2022. Prior to this, Klaus Juhl...

February 9, 2026 1 EN
 PRESS RELEASE
Free
BIOPOR BIOPORTO A/S

BioPorto leverer foreløbige, ureviderede finansielle tal for 2025, fin...

BioPorto leverer foreløbige, ureviderede finansielle tal for 2025, finansiel guidance for 2026 og en forretningsopdatering  5. februar 2026Meddelelse nr. 1 BioPorto leverer foreløbige, ureviderede finansielle tal for 2025, finansiel guidance for 2026 og en forretningsopdatering                                                                         KØBENHAVN, DANMARK, 5. februar, 2026, (GLOBE NEWSWIRE) – BioPorto A/S CVR-nr. 17500317 (BioPorto eller Selskabet) (CPH:BIOPOR), annoncerede i dag foreløbige, ureviderede finansielle tal for 2025, finansiel guidance for 2026 og en forretningsopd...

February 5, 2026 1 EN
 PRESS RELEASE
Free
BIOPOR BIOPORTO A/S

BioPorto provides Preliminary Unaudited 2025 Financial Figures, Financ...

BioPorto provides Preliminary Unaudited 2025 Financial Figures, Financial Guidance for 2026 and a Business Update  February 5, 2026Announcement no. 1 BioPorto provides Preliminary Unaudited 2025 Financial Figures, Financial Guidance for 2026 and a Business Update                                                                         COPENHAGEN, DENMARK, February 5, 2026, (GLOBE NEWSWIRE) – BioPorto A/S CVR-no. 17500317 (BioPorto or Company) (CPH:BIOPOR), today announced Preliminary Unaudited 2025 Financial Figures, Financial Guidance for 2026 and a business update.                       ...

February 5, 2026 1 EN
 PRESS RELEASE
Free
BIOPOR BIOPORTO A/S

Ændringer i selskabets Direktion

Ændringer i selskabets Direktion 11. december 2025 Meddelelse nr. 29 Ændringer i selskabets Direktion KØBENHAVN, DANMARK og BOSTON, MA, USA, 11. december 2025 (GLOBE NEWSWIRE) – BioPorto A/S ("BioPorto") (CPH:BIOPOR) meddelte i dag, at Niels Høy Nielsen har opsagt sin stilling som CFO for BioPorto for at tiltræde en CFO-stilling i et andet selskab. "Jeg har værdsat det tætte samarbejde med Niels i de sidste par måneder, siden jeg tiltrådte min stilling i BioPorto. Niels har ydet vigtige bidrag til virksomheden og jeg ønsker ham alt det bedste i hans fremtidige stilling," sagde Carsten B...

December 11, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch